Company Monitoring Page for JNJ

latest headlines for company on cafepharma

Here's a Multibillion-Dollar Market for Johnson & Johnson
Motley Fool
Tue, 04/13/21 - 10:26 am
Tags:
JNJ, Ponvory, MS, multiple sclerosis
CEOs of COVID-19 Vaccine Makers See Boost in Salaries
BioSpace
Mon, 04/12/21 - 11:00 am
Tags:
Pharma CEOs, COVID-19, executive pay, Albert Bourla, Pfizer, Ugur Sahin, BioNTech, Stephane Bancel, Moderna Therapeutics, Alex Gorsky, JNJ, Pascal Soriot, AstraZeneca
FDA joins Europe in probing rare blood clots after Johnson & Johnson's COVID-19 vaccine
Fierce Pharma
Mon, 04/12/21 - 10:45 am
Tags:
FDA, JNJ, COVID-19, vaccines, blood clots
Johnson & Johnson's COVID-19 vaccine under scrutiny at EMA after 4 'serious cases' of unusual blood clots
Fierce Pharma
Fri, 04/9/21 - 10:43 am
Tags:
JNJ, vaccines, blood clots, EMA, Europe, COVID-19
Some health systems pausing J&J vaccinations after adverse patient reactions
Beckers Hospital Review
Fri, 04/9/21 - 10:41 am
Tags:
JNJ, vaccines, COVID-19, adverse reactions
FDA inspection of Emergent’s Baltimore site in 2020 raises new questions
Endpoints
Thu, 04/8/21 - 07:46 pm
Tags:
JNJ, Emergent BioSolutions, drug manufacturing, FDA, regulatory inspections
J&J Vision and Menicon Tackle Myopia with Contact Lens Collaboration
Medical Devices and Diagnostics Industry
Wed, 04/7/21 - 07:18 pm
Tags:
JNJ, Menicon, myopia, contact lens, Japan, devices, Medtech
J&J scores backing from Chamber of Commerce, PhRMA and more in Supreme Court appeal of $2.1B talc verdict
Fierce Pharma
Wed, 04/7/21 - 07:12 pm
Tags:
JNJ, Supreme Court, PhRMA
J&J Bets Up to $780 Million on Cidara’s Universal Influenza Treatment
BioSpace
Tue, 04/6/21 - 10:07 am
Tags:
JNJ, Cidara Therapeutics, CD388, Flu
J&J to oversee vaccine production at Emergent factory that ruined doses
BioPharma Dive
Mon, 04/5/21 - 02:51 pm
Tags:
JNJ, Emergent BioSolutions, vaccines, COVID-19, drug manufacturing
Emergent's Immunoglobulin Fails COVID-19 Trial Day After J&J Vaccine Mix-Up
BioSpace
Mon, 04/5/21 - 02:34 pm
Tags:
Emergent BioSolutions, COVID-HG, clinical trials, immunoglobulin, JNJ
Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma
Endpoints
Thu, 04/1/21 - 10:53 am
Tags:
Sanofi, JNJ, Sarclisa, Kyprolis, Multiple Myeloma
15 million Johnson & Johnson coronavirus vaccines ruined due to human error
Fierce Pharma
Wed, 03/31/21 - 10:59 pm
Tags:
JNJ, vaccines, COVID-19
TikTok famous? Pfizer, Moderna, J&J and AZ shoutouts on social media boost vaccine credibility—and pharmas' image
Fierce Pharma
Tue, 03/30/21 - 10:20 pm
Tags:
Pfizer, Moderna Therapeutics, JNJ, AstraZeneca, social media, vaccines, TikTok, COVID-19
Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts
Fierce Pharma
Mon, 03/29/21 - 10:55 pm
Tags:
Bristol Myers Squibb, Bluebird Bio, CAR-T, JNJ, Legend Biotech, Abecma
Johnson & Johnson to supply African Union member states with up to 400 million COVID-19 vaccine doses
Biopharma Reporter
Mon, 03/29/21 - 10:32 am
Tags:
JNJ, AVAT, Africa, vaccines, COVID-19
J&J’s New Lenses Break the Limit for Traditional Contact Use
Medical Devices and Diagnostics Industry
Wed, 03/24/21 - 11:12 pm
Tags:
JNJ, vision, contact lenses, Ketotifen
FDA approves Janssen’s PONVORY for treatment of multiple sclerosis
Pharmaceutical Business Review
Mon, 03/22/21 - 10:35 am
Tags:
JNJ, Janssen, FDA, Ponvory, relapsing multiple sclerosis, MS
J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market
Fierce Pharma
Fri, 03/19/21 - 10:56 am
Tags:
JNJ, Ponvory, Novartis, Bristol-Myers Squibb, MS, multiple sclerosis
Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial
BioSpace
Tue, 03/16/21 - 10:40 pm
Tags:
JNJ, Janssen, clinical trials, Tremfya, psoriatic arthritis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.